Karyopharm Therapeutics share price logo

Karyopharm Therapeutics

NASDAQ: KPTI

$0.64

-0.01

(-1.17%)

as on

Karyopharm Therapeutics Stock Performance

as on October 8, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.62
    $0.69
    downward going graph

    3.47%

    Downside

    7.43%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.63
    $10.99
    downward going graph

    2.55%

    Downside

    1611.04%

    Upside

    downward going graph

Karyopharm Therapeutics share price movements today

Previous Close
$0.65
Open
$0.66
Volume
856.7K
Market Cap
$15.2M
Day's Low - High
$0.62 - $0.69
52 Week Low - High
$0.63 - $10.99

Karyopharm Therapeutics Historical Returns

1 Month Return
-63.69 %
3 Month Return
-93.53 %
1 Year Return
-88.74 %
3 Year Return
-96.64 %
5 Year Return
-99.25 %

Karyopharm Therapeutics Stock Fundamentals & Key Indicators

Check Karyopharm Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$15.2M

EPS (TTM)

-22.32

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.03

Industry PE ratio

-3.01

PEG Ratio

0.00

EBITDA

-175.9M

Revenue (TTM)

146.6M

Profit Margin

95.88%

Return On Equity TTM

77.63%

Karyopharm Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Karyopharm Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$15.2M-99.25%-0.0395.88%0.00%
StrongBuy$44.5B617.67%-23.440.00%0.00%
Neutral$81.1B-39.40%-25.46-12.57%0.00%
StrongBuy$127.9B178.32%29.1486.04%0.00%
Buy$75.7B33.82%17.3584.86%0.51%

Stock Returns calculator for Karyopharm Therapeutics Stock including INR - Dollar returns

The Karyopharm Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Karyopharm Therapeutics investment value today

Current value as on today

₹12,140

Returns

-₹87,860

(-87.86%)

Returns from Karyopharm Therapeutics Stock

-₹88,868 (-88.87%)

Dollar Impact

₹1,008 (+1.01%)

Analyst Recommendation on Karyopharm Therapeutics Stock

Based on 4 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 4 analysts, 75% of analysts recommend a 'BUY' rating for Karyopharm Therapeutics. Average target price of $7.25

Karyopharm Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Karyopharm Therapeutics.

What analysts predicted

91.14%UPSIDE

Target Price

$7.25

Current Price

$0.6423

Analyzed by

4 Analysts

High

$11

Target

$7.25

Low

$3

Karyopharm Therapeutics target price $7.25, a slight upside of 91.14% compared to current price of $0.6423. According to 4 analysts rating.

Indian Investors' Interest in Karyopharm Therapeutics Stock

Search interest for Karyopharm Therapeutics Stock has decreased by -56% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-56% versus previous 30 day period

Karyopharm Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
33
42
38
30
30
37
44
34
35
33
Gross Profit
31
41
37
29
28
36
41
32
33
32
Operating Income
-33
-28
-26
-31
-33
-24
-15
-17
-26
-22
EBITDA
-31
32
-20
-19
-12
-25
-22
-89
-9
-53
Interest Expense
5
8
11
11
10
11
11
12
12
13
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-37
23
-32
-30
-23
-37
-33
-102
-22
-67
Income Tax Expense
0
0
0
0
0
0
0
0
0
-
Net Income
-37
23
-32
-30
-23
-37
-33
-102
-22
-67
Net Profit Margin
93.97%
96.36%
96.65%
95.64%
95.67%
97.23%
95.20%
95.65%
96.13%
96.75%

Karyopharm Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
30
40
108
209
157
146
145
146
Gross Profit
-105
-131
38
105
206
151
141
139
140
Operating Income
-130
-179
-189
-171
-98
-142
-129
-119
-90
EBITDA
-128
-175
-182
-167
-96
-139
-118
-38
-149
Interest Expense
-
2
15
27
26
24
23
37
45
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-128
-178
-199
-195
-123
-164
-142
-76
-195
Income Tax Expense
0
0
0
0
0
0
0
0
0
Net Income
-128
-178
-199
-196
-124
-165
-143
-76
-196
Net Profit Margin
-6583.68%
-431.95%
94.11%
97.50%
98.38%
96.68%
96.62%
95.86%
95.93%

Karyopharm Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-37
23
-32
-30
-23
-37
-33
-102
-22
-67
Operating Cash Flow
-43
-38
-19
-25
-38
-18
-5
-11
-22
-24
Investing Cash Flow
21
51
7
14
15
18
4
5
3
-10
Financing Cash Flow
-
40
-
0
-
0
-
29
49
0
Change in Cash
-21
53
-11
-10
-23
0
-1
22
30
-35

Karyopharm Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-128
-178
-199
-196
-124
-165
-143
-76
-196
Operating Cash Flow
-73
-159
-190
-160
-107
-149
-92
-127
-75
Investing Cash Flow
17
-107
78
-53
141
-104
7
95
43
Financing Cash Flow
75
316
124
172
73
193
1
41
30
Change in Cash
19
49
11
-41
108
-60
-83
9
-1

Global Institutional Holdings in Karyopharm Therapeutics

Check out the Institutions with significant holdings in Karyopharm Therapeutics.

Funds
Holdings
Peter Kolchinsky
8.45%
MUTUAL FUND SERIES TRUST
4.96%
Vanguard
4.74%
T. ROWE PRICE SMALL-CAP VALUE FUND, INC.
3.86%
iShares
3.28%

Karyopharm Therapeutics News & Key Events

  • img

    Today's Timeline - 11 September

    Fri, 05:25 PM

    -

    Karyopharm enters forbearance agreement, delaying $15.8M debt payment and allowing time for negotiations and strategic alternatives.

Insights on Karyopharm Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 585.7% return, outperforming this stock by 674.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 80.5% return, outperforming this stock by 177.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 35.06M → 33.43M (in $), with an average decrease of 4.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, KPTI stock has moved down by -46.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -22.39M → -67.02M (in $), with an average decrease of 199.3% per quarter

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
OrganisationKaryopharm Therapeutics
Headquarters85 Wells Avenue, Newton, MA, 02459-3298, US
IndustryBiotechnology
CEORichard A. Paulson

Key Management of Karyopharm Therapeutics

Name

Title

Mr. Richard A. Paulson M.B.A.

President, CEO & Director

Mr. Stuart Poulton

Executive VP & Chief Development Officer

Dr. Sharon Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Mr. Michael J. Mano J.D.

Executive VP, Chief Legal Officer & Secretary

Ms. Lisa DiPaolo

Executive VP & Chief Human Resource Officer

Dr. Reshma Rangwala M.D., Ph.D.

Executive VP, Chief Medical Officer & Head of Research

Ms. Lori A. Macomber CPA

EVP, CFO & Treasurer

Ms. Kristin Abate

VP, Chief Accounting Officer & Assistant Treasurer

Mr. Brendan Twohig Strong

Senior Vice President of Investor Relations

Mr. James Accumanno J.D.

Chief Compliance Officer

FAQs

What is Karyopharm Therapeutics share price today?

Karyopharm Therapeutics share price today is $0.64 as on at the close of the market. Karyopharm Therapeutics share today touched a day high of $0.69 and a low of $0.62.

What is the 52 week high and 52 week low for Karyopharm Therapeutics share?

Karyopharm Therapeutics share touched a 52 week high of $10.99 on and a 52 week low of $0.63 on . Karyopharm Therapeutics stock price today i.e. is closed at $0.64,which is 94.16% down from its 52 week high and 2.62% up from its 52 week low.

What is Karyopharm Therapeutics's market capitalisation today?

Karyopharm Therapeutics market capitalisation is $0.00T as on .

How to invest in Karyopharm Therapeutics Stock (KPTI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Karyopharm Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Karyopharm Therapeutics Stock (KPTI) from India?

Indian investors can start investing in Karyopharm Therapeutics (KPTI) shares with as little as ₹96.775001525879 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹967.75 in Karyopharm Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Karyopharm Therapeutics share’s latest price of $0.64 as on October 8, 2026 at 1:29 am IST, you will get 15.5690 shares of Karyopharm Therapeutics. Learn more about fractional shares .

What are the returns that Karyopharm Therapeutics has given to Indian investors in the last 5 years?

Karyopharm Therapeutics stock has given -99.25% share price returns and 28.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?